The use of cilostazol in patients with peripheral arterial disease: Results of a national physician survey

Journal of Cardiovascular Surgery

Volumn 57, Issue 3, 2016, Pages 457-465

  De Donato, Gianmarco ^a   Setacci, Francesco ^a   Galzerano, Giuseppe ^a   Mele, Mariagnese ^a   Ruzzi, Umberto ^a   Setacci, Carlo ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Intermittent claudication; Peripheral arterial disease; Surveys and questionnaires

Indexed keywords

CILOSTAZOL; TETRAZOLE DERIVATIVE; VASODILATOR AGENT;

ARTICLE; CLAUDICATION; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; HEALTH CARE SURVEY; HEART MUSCLE REVASCULARIZATION; HUMAN; INTERNIST; PATIENT COMPLIANCE; PATIENT SELECTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICIAN ATTITUDE; PRESCRIPTION; TREATMENT DURATION; VASCULAR SURGEON; FEMALE; ITALY; MALE; PERIPHERAL ARTERIAL DISEASE; QUALITY OF LIFE; STATISTICS AND NUMERICAL DATA;

CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; ITALY; MALE; PATIENT SELECTION; PERIPHERAL ARTERIAL DISEASE; PRACTICE PATTERNS, PHYSICIANS'; QUALITY OF LIFE; TETRAZOLES; VASODILATOR AGENTS;

EID: 84990061970     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation 1995;91:1472-9.
2. Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G. Cilostazol for intermittent claudication. Cochrane Database Syst Rev 2014;10:CD003748.
3. Aronow WS, Nayak D, Woodworth S, Ahn C. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 2003;92:711-2.
4. Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects treating intermittent claudication: results from a multi-center, randomized, prospective, double-blind trial. Circulation 1998;98:678-86.
5. Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE Jr, Bortey EB, et al. A new pharmacologic treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999;159:2041-50.
6. Money SR, Herd JA, Isaacsohn JL, Davidson M, Cutler B, Heckman J, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998;27:267-74.
7. Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg 2012;99:1630-8.
8. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic). A Collaborative Report From the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine and Biology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease [Lower Extremity, Renal, Mesenteric, and Abdominal Aortic]). Circulation 2006;113:e463-654.
9. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007;45(Suppl):S5-S67.
10. Alonso-Coello P, Bellmunt S, McGorrian C, Anand S, Guzman R, Criqui M. et al. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 2012;141(Suppl):e669S-90S
11. Aiello A, Anichini R, Brocco E, Caravaggi C, Chiavetta A, Cioni R, et al. Treatment of peripheral arterial disease in diabetes: A consensus of the Italian Societies of Diabetes (SID, AMD), Radiology (SIRM) and Vascular Endovascular Surgery (SICVE). Nutr Metab Cardiovasc Dis 2014;24:355-69.
12. Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000;109:523-30.
13. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: A study in long-term effects). J Vasc Surg 2008;47:330-6.
14. de Liefde II, Klein J, Bax JJ, Verhagen HJ, van Domburg RT, Poldermans D. Exercise ankle brachial index adds important prognostic information on long-term out-come only in patients with a normal resting ankle brachial index. Atherosclerosis 2011;216:365-9.
15. Iida O, Nanto S, Uematsu M, Morozumi T, Kitakaze M, Nagata S. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg 2008;48:144-9.
16. Iida O, Yokoi H, Soga Y, Inoue N, Suzuki K, Yokoi Y, et al.; STOPIC investigators. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation 2013;127:2307-15.
17. Lee S-W, Ahn J-M, Han S, Park G-M, Cho Y-R, Lee WS, et al. Differential impact of cilostazol on restenosis according to implanted stent type (from a pooled analysis of three DECLARE randomized trials). Am J Cardiol 2013;112:1328-34.
18. Bangalore S, Singh A, Toklu B, DiNicolantonio JJ, Croce K, Feit F, et al. Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials. Open Heart 2014;1:e000068.
19. Warner CJ, Greaves SW, Larson RJ, Stone DH, Powell RJ, Walsh DB, et al. Cilostazol is associated with improved outcomes after peripheral endovascular interventions J Vasc Surg 2014;59:1607-14.
20. Neel JD, Kruse RL, Dombrovskiy VY, Vogel TR. Cilostazol and freedom from amputation after lower extremity revascularization. J Vasc Surg 2015;61:960-4.
21. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: A review from the patient's perspective. Ther Clin Risk Manag 2008;4:269-86.
22. Dawson DL, DeMaioribus CA, Hagino RT, Light JT, Bradley DV Jr, Britt KE, Charles BE. The effect of withdrawal of drugs treating intermittent claudication. Am J Surg 1999;178:141-6.
23. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007;45(Suppl):S5-S67.
24. Society for Vascular Surgery Lower Extremity Guidelines Writing Group; Conte MS, Pomposelli FB, Clair DG, Geraghty PJ, McKinsey JF, Mills JL, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: Management of asymptomatic disease and claudication. J Vasc Surg 2015;61:2S-41S.